I partner with life sciences and technology companies to accomplish their general legal objectives, as well as guide them through financing transactions and public company reporting and compliance.
+1 858 550 6034 sclayton@cooley.com
Sean Clayton's practice focuses on the representation of public and private growth companies in general corporate matters, as well as a wide range of transactions, including public offerings, venture capital financings and M&A.
Download full bio
Inhibrx – $137 Million IPO
Poseida Therapeutics – $224 Million IPO
Pliant Therapeutics - $166 Million IPO
ORIC Pharmaceuticals - $138 Million IPO
Phathom Pharmaceuticals - $209 Million IPO
View all
Capital Markets
Public Companies
Emerging Companies
Mergers & Acquisitions
Venture Capital
Family
Sports
Brewing
Don’t know how Cooley does it but they always pull out great attorneys to work with and you are certainly that. We really appreciate your knowledge, experience and counsel through this process.
Stanford Law SchoolJD, Order of the Coif, 2003
University of California, San DiegoBA, Political Science and Economicssumma cum laude, Phi Beta Kappa, 2000
California
Gossamer Bio – $317 Million IPO February 21, 2019
ASLAN Pharmaceuticals – $42 Million IPO June 8, 2018
Vital Therapies – $40 Million Follow-on Offering March 29, 2017
+1 858 550 6034 office +1 858 550 6420 fax sclayton@cooley.com
4401 Eastgate MallSan Diego, CA 92121-1909